^
PTPRT mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Med - 2 days
PD-L1 expression
NSCLC
pembrolizumab + lenvatinib
Sensitive: B - Late Trials
ESMO-IO 2021 - 4 days
EGFR L858R
NSCLC
tislelizumab
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 4 days
EGFR exon 19 deletion
NSCLC
tislelizumab
Sensitive: C3 – Early Trials
ESMO-IO 2021 - 4 days
ALK mutation
NSCLC
crizotinib + alectinib
Sensitive: C3 – Early Trials
Thorac Cancer - 5 days
HER-2 exon 20 mutation
NSCLC
HM 78136B
Sensitive: B - Late Trials
J Clin Oncol - 1 week
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
Sci Rep - 6 days
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
Invest New Drugs - 2 weeks
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
Clin Cancer Res - 2 weeks
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
Roche Press Release - 2 weeks
EGFR T790M
NSCLC
aumolertinib
Sensitive: A1 - Approval
J Thorac Oncol - 2 weeks
PD-L1 expression
NSCLC
MT-6402
Sensitive: B - Late Trials
Molecular Templates Press Release - 2 weeks
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: B - Late Trials
Ann Oncol - 2 weeks
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
Thorac Cancer - 2 weeks
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: C3 – Early Trials
Thorac Cancer - 2 weeks
HER-2 D769Y
LUAD
afatinib + anlotinib
Sensitive: C4 – Case Studies
World J Surg Oncol - 2 weeks
EGFR E709_T710delinsD
NSCLC
afatinib
Sensitive: C4 – Case Studies
J Med Case Rep - 2 weeks
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
Amgen Press Release - 3 weeks
TMB-H
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
MET amplification
NSCLC
c-MET inhibitor
Sensitive: C3 – Early Trials
Exp Hematol Oncol - 3 weeks
TMB-H
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
EGFR L747_T751delinsP
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
PD-L1 expression + EGFR mutation
NSCLC
pembrolizumab
Sensitive: C4 – Case Studies
J Oncol Pharm Pract - 2 weeks
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive: A2 - Guideline
SITC 2021 - 3 weeks
KRAS mutation
NSCLC
Immunotherapy
Sensitive: B - Late Trials
SITC 2021 - 3 weeks
STK11 mutation
NSCLC
BGB324
Sensitive: B - Late Trials
BerGenBio Press Release - 3 weeks
STK11 mutation
NSCLC
pembrolizumab + BGB324
Sensitive: B - Late Trials
SITC 2021 - 3 weeks
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
SITC 2021 - 3 weeks
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
SITC 2021 - 3 weeks
TMB-H
NSCLC
pembrolizumab
Sensitive: C1 - Off-label
SITC 2021 - 3 weeks
HER-2 amplification
NSCLC
pyrotinib
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 weeks
PD-L1 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TNFRSF14 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TNFRSF18 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TMB-H
NSCLC
pembrolizumab + MK-1308
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TMB-H
NSCLC
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
EGFR expression
NSCLC
cetuximab + CYNK-101
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
pemetrexed
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
LUAD
nintedanib
Sensitive: A1 - Approval
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
ALK positive
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
amivantamab-vmjw
Sensitive: A1 - Approval
No biomarker
NSCLC
docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib
Sensitive: A1 - Approval
ALK positive
NSCLC
ceritinib
Sensitive: A1 - Approval
No biomarker
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib + Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
ALK mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
entrectinib
Sensitive: A1 - Approval
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
ALK positive
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
cemiplimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H
NSCLC
nivolumab + ipilimumab
Sensitive: A2 - Guideline
ROS1 fusion
NSCLC
crizotinib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
ceritinib
Sensitive: A2 - Guideline
ROS1 rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
crizotinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
alectinib
Sensitive: A2 - Guideline
ROS1 positive
NSCLC
lorlatinib
Sensitive: A2 - Guideline
EGFR mutation
NSCLC
osimertinib
Sensitive: A2 - Guideline
ALK rearrangement
NSCLC
ALK inhibitor
Sensitive: A2 - Guideline
EGFR exon 19 mutation
NSCLC
erlotinib
Sensitive: A2 - Guideline
BRAF V600E
NSCLC
vemurafenib
Sensitive: A2 - Guideline
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A2 - Guideline